Poolbeg Pharma could reach €1bn valuation, says chief executive

Dublin-headquartered biopharma company is targeting the growing infectious disease market

Jeremy Skillington, chief executive of Poolbeg Pharma: ‘it’s a case of Amyrt 2.0, let’s do this again.’ Picture: Fergal Phillips

Poolbeg Pharma, the Dublin-headquartered biopharmaceutical company, could reach a €1 billion valuation, according to Jeremy Skillington, its chief executive.

Skillington compared the potential of Poolbeg to that of Amryt Pharma, which was sold to Chiesi Farmaceutici for $1.48 billion in April. Both companies were co-founded by serial entrepreneur Cathal Friel.

Poolbeg, which was spun out of Open Orphan (now Hvivo), in 2021, is targeting the growing infectious disease market.

It recently announced that David Allmond, ...